我們已在上線!
進一步了解
LJPC
La Jolla Pharmaceutical Company
LJPC
LJPC
已下市
LJPC已於2022年8月19日下市。
關於: La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
員工: 66
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於LJPC的最新新聞文章。
價格圖表採用Lightweight Charts™實作